In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing ...

Star hopes its drug, which is currently in late-stage testing, might prove a more convenient, longer-lasting alternative to ...

The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect ...

The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

Walmsley, who helped push GSK to focus more exclusively on specialty medicines and oncology, will be succeeded by commercial ...

After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling ...

Anticipated late-stage results in the skin disease hidradenitis suppurativa were described by analysts as “disappointing” and ...